{"id":18369,"date":"2026-06-09T22:00:00","date_gmt":"2026-06-09T20:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=144c893e08d9f613e5b1d98992715328"},"modified":"2026-06-09T22:00:00","modified_gmt":"2026-06-09T20:00:00","slug":"abl-diagnostics-ordinary-and-extraordinary-general-meeting-of-june-30-2026-terms-for-making-available-or-consulting-preparatory-documents","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18369","title":{"rendered":"ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 \u2013 Terms for Making Available or Consulting Preparatory Documents"},"content":{"rendered":"<p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p><p>\nABL Diagnostics (Paris:ABLD) informs its shareholders that they are invited to attend the Ordinary and Extraordinary General Meeting to be held on Tuesday, June 30, 2026, at 11:00 a.m., at the premises of the law firm De Gaulle Fleurance &amp; Associates, located at 9 rue Boissy d\u2019Anglas \u2013 75008 Paris.<\/p><p>\nThis Meeting will, in particular, be called upon to rule on the annual financial statements for the financial year ended December 31, 2025.<\/p><p>\nThe preliminary notice of meeting, including the agenda, the text of the resolutions, and the main procedures for participation and voting at this Meeting, was published in the Bulletin des Annonces L\u00e9gales Obligatoires (BALO) on May 22, 2026.<\/p><p>\nThis notice of meeting and all documents relating to this Meeting referred to in Article R.22-10-23 of the French Commercial Code may be consulted on the Company\u2019s website: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abldiagnostics.com&amp;esheet=54550528&amp;newsitemid=20260609253739&amp;lan=en-US&amp;anchor=www.abldiagnostics.com&amp;index=1&amp;md5=edc9155e6f9fce747ad6385e980e6662\" rel=\"nofollow\" shape=\"rect\">www.abldiagnostics.com<\/a>.<\/p><p>\nThe other documents and information relating to this Meeting are also available to shareholders under the applicable legal and regulatory conditions.<\/p><p>\n<b>About ABL Diagnostics (ABLD)<\/b><\/p><p>\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p><ul class=\"bwlistdisc\">\n<li>\nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n<li>\nGenotyping by DNA sequencing \u2013 DeepChek\u00ae.<\/li>\n<\/ul><p>\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p><p>\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p><p>\n<b>An expanding portfolio of microbiology products:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n<li>\nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n<li>\nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n<li>\nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul><p>\n<b>Integrated Solutions<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nReal-time syndromic PCR tests<\/li>\n<li>\nNadis\u00ae \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n<li>\nMediaChek\u00ae \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul><p>\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABL Diagnostics SA<\/b><br\/>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\n<br\/>Headquarters : 72C route de Thionville - 57140 WOIPPY\n<br\/>552 064 933 R.C.S. METZ<\/p><p>\nTel : +33 (0)7 83 64 68 50\n<br\/>Email : <a  href=\"mailto:info@abldiagnostics.com\" rel=\"nofollow\" shape=\"rect\">info@abldiagnostics.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;esheet=54550528&amp;newsitemid=20260609253739&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;index=2&amp;md5=81334ad7579f23f9e99050debd7dd98c\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>WOIPPY, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<br \/>\nABL Diagnostics (Paris:ABLD) informs its shareholders that they are invited to attend the Ordinary and Extraordinary General Meeting to be held on Tuesday, June 30, 2026, at 11:00 a.m., at the premises &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18369","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18369"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18369\/revisions"}],"predecessor-version":[{"id":18370,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18369\/revisions\/18370"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}